Annovis Bio
Annovis up 23% after webinar on neurodegeneration candidates
Thinly traded nano cap Annovis Bio (ANVS +22.6%) bucks the broad market's bearishness, albeit on turnover of only 54K shares. After the close yesterday, CEO Maria Maccecchini, Ph.D., hosted an online Q&A session about recent developments at the company.
Thinly traded nano cap Annovis Bio (ANVS +22.6%) bucks the broad market's bearishness, albeit on turnover of only 54K shares. After the close yesterday, CEO Maria Maccecchini, Ph.D., hosted an online Q&A session about recent developments at the company.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.